Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Trial finds lopinavir/ritonavir and Arbidol ineffective for mild-to-moderate COVID-19

europeanpharmaceuticalreviewApril 22, 2020

Tag: lopinavir/ritonavir , Arbidol , COVID-19

PharmaSources Customer Service